Thanks to yeboha on LSE:
Notable peptide-drug conjugate companies such as Novartis AG, Oncopeptides AB, Cybrexa Therapeutics, Avacta Therapeutics, |
So, anyway, you waiting for mid 30 still before you buy back in? |
You're a proper Sherlock Holmes, Miss Marple, Hercule Poirot all rolled into one aren't you. You figured me out with my pseudonyms. So clever. LOL more like an Inspector Clouseau. |
Hamida is Raj.Always has been.Trapped is our Raj poor lad. Wait til 41p ish, then pray.Sorted. |
Nice. The plan starts to unfold. First job for the broker is to get this back to £1!! |
joint broker appointment means confetti party soon |
Raj trapped ,hence the verbals. Wait young child, wait. Overvalued on any metric. |
"Errrrrrr..."You ok Amaan? You got trapped wind or something? |
Thanks to RAH on X
@RAH00084
The market is still yet to cotton on to the significance of #AVCT delivering straight dox.
Straight dox. Not a novel compound.
It’s why the FDA route will likely be eased (now safety is proven) but also why the risk of failure is far lower than a normal P1b drug.
So as you say, what AVCT sits on is not just a solution which delivers an ‘old’ drug (thus making the regulatory path far easier) but one which is also behaving in a different way because of the impact it’s causing on the stroma/TME etc.
The impact of taking an old drug and changing the way it inhibits (without actually changing its pre-cleavage chemical structure) is an incredibly exciting proposition, given the FDA views this as ‘just dox’ from a chemical/regulatory perspective.
We spent so much time (pre-efficacy results) talking about the risks of tumour evasion and the mechanism dox builds to promote resistance.
We’re now talking about how AVA6000 manages to kill cancer after the dosing stops… |
Errrrrrr... |
Errrrrrr... |
https://i.dailymail.co.uk/1s/2025/01/24/21/94489731-14322641-image-a-11_1737753553374.jpg |
It.s very poor here ...still trading in the usual range, pinned by the death spiral.When will it all end??? |
Oodles of shares issued at just 45.77p: |
Ahh - in stumbles 1347 like the drunken village idiot. Still shouting about yer sub 40p sp? Thought not. |
Death spriral loan conversion due tomorrow, are they going to pay in cash? Personally I doubt it and it looks like it was already foward sold in that last little mini spike. Remind me, when in 2024 is Phase II of AVA6000 starting? |
Amaan, you still waiting for the mid 30's before you buy back in again? |
"I would go one step further and question if any of their efficacy results showed any tumour shrinkage at all."
Sorry, but that implies fraudulent reporting, which you have categorically said is NOT the case? (on numerous occassions). Are you changing your tune on this? |
King Suarez - "PW is saying, as he keeps maintaining, that DOX is not being released at all by AVA6K and that any of the efficacy results being show are in line with the random chance that some tumours shrink of their own accord."
That's exactly what I'm saying and why the safety record is 100% at all dosage levels. I would go one step further and question if any of their efficacy results showed any tumour shrinkage at all. |
Absolutely vertizeasun .
Just the financial so called,’death spiral,hanging over the finance . |
"It's telling us that 90% of the people who took this drug saw their #cancer tumour growth halted in its tracks and 50% of them are seeing tumours SHRINK
These patients are end of life, and are heavily pre-treated with metastatic cancers, basically it's as bad as it can get. They've exhausted all other options, their cancers have built up resistance to treatments so they're just waiting to DIE. Seeing ANY efficacy at all is a miracle, given this is just a safety trial - yet here we are." |
You could write a book about the Avacta story or maybe someone will make a film. On this thread we have a mixture of LTHs, Traders, shorters, those who think it doesn't work while over on LSE there's now a new line of FUD saying it works too well. Laughable. |
Closed short today, 51 (posn 74).
I'll await the death spiral. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
